@article{97,
  keywords = {Adult, Brazil, Clofazimine, Dapsone, Drug Therapy, Combination, Female, Humans, Leprostatic Agents, leprosy, Male, Middle Aged, Retrospective Studies, Rifampin, Treatment Outcome},
  author = {Deps PD and Nasser S and Guerra P and Simon M and Birshner RDC and Rodrigues L},
  title = {Adverse effects from multi-drug therapy in leprosy: a Brazilian study.},
  abstract = {<p><b>INTRODUCTION: </b>The WHO MDT for leprosy treatment was officially introduced in Brazil in 1991 and comprises three drugs: dapsone, rifampicin and clofazimine. There are few good studies on the frequency of side-effects attributable to MDT in Brazil.</p><p><b>METHODS: </b>A retrospective and descriptive study carried out in a LCP in Vitória, State of Espirito Santo, Brazil. A specific and detailed protocol about side-effects was prepared and filled in from the patient records.</p><p><b>RESULTS: </b>One hundred ninety four patients' records were analysed looking for side-effects attributable to MDT. Side-effects were attributed to at least one MDT component in 88 (45%) patients and 85 had side-effects due to dapsone, 24 due to rifampicin and 18 due to clofazimine. 185 episodes were identified. The suspected drug was stopped in 47 out of 88 episodes (24% patients); 46 had dapsone stopped, 5 had rifampicin stopped and no-one had clofazimine stopped.</p><p><b>CONCLUSION: </b>Side-effects attributed to MDT is more frequent than previously described, resulting in interruption of treatment in many patients.</p>},
  year = {2007},
  journal = {Leprosy review},
  volume = {78},
  pages = {216-22},
  month = {2007 Sep},
  issn = {0305-7518},
  url = {https://leprosyreview.org/article/78/3/21-6222},
  language = {eng},
}